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1. Introduction 
1.1 The innate immune system 
Our bodies are under constant attack from pathogens. Despite this continual bombardment, 
under normal circumstances we remain healthy for most of our lives. This protection against 
infectious and harmful agents is provided by our immune system. The immune system can 
be broken into two elements: adaptive immunity and innate immunity. Adaptive immunity 
is a specific response targeted against particular pathogens through, for example, cytotoxic 
T cells and antibody production. The adaptive immune system has the potential to raise a 
defence against any invading pathogen. However, this is a relatively slow and energy 
expensive process. Innate immunity in contrast provides a non-specific response against any 
pathogen via a variety of components and processes. These include: barrier functions, 
complement, natural killer (NK) cells, antimicrobial peptides, mucosal secretions, pattern 
recognition receptors (PRRs) and the commensal micro-organisms. Innate immunity is 
responsible for clearing the majority of pathogen exposures that would result in infection 
before the adaptive system is even involved. This chapter will focus upon the role of one 
particular arm of the innate immune response to infectious diseases – Pattern Recognition 
Receptors. It will broadly address the mechanisms by which PRRs recognise the pathogens, 
the effects this has and the types if response it has. It will also bring in examples of evasion 
strategies used by pathogens to avoid detection and touch on the impact of polymorphisms 
in the receptors. Finally we will discuss the role of PRRs in a key defence against infectious 
diseases, vaccination. 
1.2 Targets for innate immune recognition by PRRs 
PRRs are protein molecules encoded in the genome and not subject to rearrangement or 
variation during the lifetime of an individual. PRRs function as molecular sensors of 
infection and are predominantly found on critical immune cells such as macrophages and 
dendritic cells (DC). However, other cell types likely to come into contact with pathogens, 
for example epithelial cells, also express subsets of these receptors. Given the absence of 
functional rearrangement how do PRRs recognise pathogens from diverse families 
possessing such diverse biology and patterns of infection? 
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Firstly, the innate immune system is designed to recognise biological components that are 
common to many pathogens. These are known as pathogen-associated molecular patterns 
(PAMPs). This means, for example, that a receptor is able to respond to all bacteria that have 
common components in their cell walls rather than a specific protein that is found on only 
one type of micro-organism (Table 1).  
Secondly, there are a number of families of receptors, and many receptors in each family 
(Section 2, Table 1). This limited diversity allows the innate immune system to respond, not 
only to different PAMPs, but also PAMPs found in either the extracellular space or an 
intracellular environment. By having multiple sites for detection of diverse targets, it is 
unlikely that any given pathogen will be able to evade all of the levels of detection. 
Thirdly, and most importantly, the receptors are able to mount a coordinated response to 
pathogen infection because of extensive cross-talk and communication between the different 
signalling pathways. This again minimises the possibility of a pathogen being able to evade 
the innate immune response. Overall, the innate immune response is primarily designed to 
induce inflammation at the site of infection, recruit inflammatory cells and mediators and 
begin to potentiate the adaptive immune system. The coordinated nature of the innate 
response ensures that any response initiated is robust enough to meet the threat. 
 
Stimulatory Pathogen 
Associated Molecular 
Pattern (PAMP) 
Pattern Recognition 
Receptor (PRR) 
Signalling 
Adapter Protein
Transcriptional or 
Cellular Pathway 
Activated 
Toll-like receptors (TLRs) 
Bacterial cell wall 
components 
TLR2 
homo/heterodimers MyD88 NFκB / AP1 
LPS TLR4 (plasma membrane) MyD88 NFκB / AP1 
LPS TLR4 (endosome) TRIF IRF3 / NFκB / AP1 
Flagellin TLR5 MyD88 NFκB / AP1 
dsRNA TLR3 TRIF IRF3 / NFκB / AP1 
ssRNA TLR7 MyD88 IRF7 / NFκB 
Nod-like receptors (NLRs) 
iE-DAP NOD1 RIP2 NFκB 
MDP NOD2 RIP2/CARD9 NFκB / AP1 
e.g. Pore-forming 
toxins, nucleic acid NLRP3 ASC Caspase-1 activation 
Retinoic acid-inducible gene I-like receptors (RLRs) 
dsRNA RIG-I MAVS IRF3 / AP1 / NFκB 
C-type lectin receptors (CLRs) 
β-glucans Dectin-1 Syk NFκB 
Table 1. Pattern Recognition Receptor (PRR) Activation and Outputs. The activation and 
signalling of PRRs is a complex, multi-factorial process. Activatory ligands (blue column) 
are recognised by specific PRRs (pink column). This leads to the recruitment of adaptor 
signalling proteins (lilac column) and the activation of intracellular signalling cascades. The 
net result is the up-regulation of transcriptional activators or specific cellular processing 
events (green column). 
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1.3 Innate immune signalling overview 
PRR activation and signalling is a complex multifactorial process that results in remarkably 
similar outcomes (Figure 1). For example: upregulation of NFB (Nuclear Factor kappa B) 
and IRF (interferon (IFN) regulatory factor) family transcription factors; stimulation of the 
stress kinase pathways (e.g. mitogen-activated protein kinases (MAPK)); and activation of 
caspase-1 (Figure 1). Ultimately this results in up-regulation of pro-inflammatory cytokines, 
chemokines and anti-viral proteins. PRRs are activated by PAMPs. Endogenous molecules, 
such as ATP and heat shock proteins, can also act as ligands for some PRRs. These 
endogenous ligands are collectively known as damage associated molecular patterns 
(DAMPs). PRR activation results in conformational changes in the proteins, activates 
intracellular signalling pathways to amplify the signal and initiates the innate response 
(Figure 1). Assembly of the downstream signalling complex is reliant on the involvement of 
specific adapter proteins to recruit signalling components and act as molecular scaffolds for 
complex assembly. PRRs use specific adaptors and different adaptor proteins result in the 
activation of different signalling pathways (see Section 2; Table 1).  
1.4 Physiological outcomes of innate immune activation 
The targets of the transcription factors produced as a result of PRR stimulation are pro-
inflammatory effectors, the most important of which are tumour necrosis factor (TNF), 
interleukin (IL)-1 and IL-6. The pro-inflammatory signals modify the permeability of the 
vasculature around a site of infection to increase recruitment of specialised immune cells, 
such as monocytes and macrophages. This leads to the classic signs of infection; redness, 
heat, swelling and pain. At a cellular level these effectors can regulate cellular death in 
localised areas of infection, but also coordinate events in the whole body through the 
activation of the acute-phase response. The production of anti-viral type I IFNs induces 
apoptosis in infected cells, thereby removing the virus from the system, but also triggers 
resistance to viral infection in neighbouring cells and so helps restrict the spread of 
infection. 
 
Fig. 1. Overview of innate immune signalling pathways and components. Activation begins 
with recognition of a stimulatory ligand, such as a pathogen-associated molecular pattern 
and results in an inflammatory or antiviral response from the cell. 
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The cellular and molecular changes associated with PRR activation are both complex and 
subtle. They create a response that can be shaped to deal with the specific nature of the 
infection. In macrophages many genes that modify their direct involvement in fighting 
infection and help repair damaged tissues are activated in response to PRR stimulation. 
Other cells, including monocytes, neutrophils, T-cells and B-cells can also be recruited to 
either directly help with the immune response or aid in the activation of the adaptive 
immune system. 
2. Pattern recognition receptor families 
PRRs are classified into four main families: Toll-like receptors (TLRs); Nucleotide binding 
leucine rich repeat (NLR) containing receptors, also known as NOD-like receptors; Retinoic 
acid-inducible gene I (RIG-I)-like receptors; and the C-type lectin receptors. The following 
sections provide brief details on the general signalling strategy of each of these families as 
well as specific examples of stimulatory ligands and physiological responses. 
2.1 Toll-like receptors (TLRs) 
TLRs are type 1 membrane proteins. They were the first components discovered in what we 
now regard as the innate immune system. TLRs use leucine-rich repeats (LRRs) to detect 
and bind ligand (Monie et al., 2009). LRRs have a conserved structural backbone which 
provides a scaffold on which variation can be built (Figure 2). Hence, LRRs from different 
receptors recognise a diverse range of PAMPs. In humans, TLR1, 2, 4, 5, 6 and 10 project 
their LRRs into the extracellular space, whereas TLR3, 7, 8 and 9 are compartmentalised to 
sample the contents of the endosomes. 
TLRs signal in dimeric complexes after ligand binding (Figures 2 and 3). In general these are 
homodimeric complexes except for TLR2 which forms a heterodimer with TLR1 or TLR6. It 
has also been reported that TLR4 is capable of forming a signalling complex with TLR6. 
However, in this instance the receptor is involved in sterile inflammation and, in 
conjunction with CD36 responds to endogenous danger signals rather than PAMPs (Stewart 
et al., 2009). It is conceivable that following activation multiple dimeric TLR receptors 
cluster together in specific regions of the cellular membrane in order to augment signalling. 
Extracellular TLRs generally recognise components found on the outer surfaces of 
pathogens, such as lipoproteins and flagellin. Endosomal TLRs meanwhile recognise nucleic 
acids such as CpG-DNA, double-stranded RNA (dsRNA) and single stranded RNA 
(ssRNA). 
The cytoplasmic Toll/IL-1 receptor (TIR) domain (Figure 2) mediates downstream 
signalling through adaptor recruitment. Based upon adaptor usage TLR signalling can be 
divided into two categories; those that signal through the protein myeloid differentiation 
factor 88 (MyD88) and those that don’t. MyD88 is recruited to the TIR domains of an 
activated TLR and results in the formation of a multiprotein complex termed the 
myddosome (Figure 3). The myddosome contains a number of IL-1R-associated kinases 
(IRAKs) which direct signalling down specific pathways. Firstly, degradation of the 
inhibitory protein IκB (inhibitor of kappa B) releases the transcription factor NFκB; and 
secondly, the MAP (mitogen activated protein) kinase pathway activates the c-fos/jun 
transcription factor. These signals combine to drive expression of pro-inflammatory 
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cytokines from NFκB and AP1 responsive genes respectively. The endosomal TLRs use the 
same pathway to activate NFκB and members of the IRF-family of transcription factors that 
activate expression of type I interferons needed to combat viral infection.  
 
Fig. 2. Selected secondary structures of functional domains from PRRs. (A) Leucine rich 
repeat (LRR) containing ectodomains of TLR1 (blue) and TLR2 (purple). The synthetic 
ligand PAM3CYK4 (orange) stimulates heterodimerisation and formation of a signalling 
competent complex. (B) Toll/IL-1 receptor (TIR) domain of TLR2. The central beta-sheet 
core (yellow) is surrounded by five alpha helices. The BB loop, between the second beta-
sheet and second alpha helix, is coloured blue. The BB loop is a key region of the TIR 
domain for downstream signalling activation and adaptor recruitment. (C) The caspase 
activation and recruitment domain (CARD) of the NLR family member NOD1. The CARD 
domain is a six-helix bundle involved in protein-protein interactions.  
The MyD88-independent pathways use the adapter TIR-related adaptor protein inducing 
IFNβ (TRIF) in combination usually with the adaptor protein TRAM (TRIF-related adaptor 
molecule). This pathway is used to drive expression of IFN-β either in response to dsRNA 
detection by TLR3, or TLR4 signalling from the endosome rather than the plasma 
membrane. There is however significant cross-talk between the pathways. Adaptor proteins 
have recently been shown to be important in the susceptibility to infectious disease. This is 
exemplified by the adaptor Mal (MyD88-adaptor like), which is involved in recruitment of 
MyD88 to the TIR domain of TLR2 and TLR4. In this instance heterozygotic carriage of a 
single nucleotide  polymorphism that results in the amino acid change serine to leucine at 
residue one-hundred-and-eighty in the TIR domain appears to be protective against the 
development of sepsis, invasive pneumococcal disease, bacteremia, malaria and tuberculosis 
(Ferwerda et al., 2009a; Khor et al., 2007) 
2.2 Nucleotide binding leucine rich repeat containing receptors (NLRs) 
The NLRs are a large family of cytoplasmic PRRs, of which there are at least 23 members. 
They share a characteristic domain organisation comprising of an N-terminal protein 
interaction domain, a central nucleotide binding region and C-terminal leucine-rich repeats 
(Figure 2). Currently the precise method of receptor activation by all the different ligands 
remains to be elucidated for the NLR family. There are two main groups in the NLR family 
based on the nature of their N-terminal domain. These are the NLRC sub-family who 
possess caspase activation and recruitment domain (CARDs) (Figure 2), and the Pyrin 
domain containing NLRP sub-family. 
A B C
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Fig. 3. Simplified schematic of TLR signalling exemplified by TLR4. Ligands are coloured 
blue, receptors are red, adaptor proteins purple, pro-inflammatory transcription factors 
green, and cellular outputs orange.  
NLR signalling pathways can be broadly split into two: 1) upregulation of NFB and 
activation of pro-inflammatory genes; 2) Inflammasome formation, caspase-1 activation and 
secretion of IL-1 and IL-18 (Figure 4). The first pathway is utilised by the prototypical NLRC 
family members NOD1 and NOD2. These receptors bind to PAMPs derived from bacterial 
peptidoglycan (Table 1). The activated NLRs signal through the adapter Receptor Interacting 
Protein 2 (RIP2) to drive the release of NFκB into the nucleus by the same processes employed 
by TLRs. In a further demonstration of PRR cross-talk, Nod2 also activates the MAP kinase 
pathway using a different adapter, CARD9, to upregulate pro-inflammatory gene expression 
from AP1 dependent promoters. The inflammasome forming NLRs consist, to date, of NLRP1, 
NLRP3 and NLRC4. The NLRP family members recruit the protein ASC (apoptosis-associated 
speck-like protein containing a CARD) through homotyoic Pyrin:Pyrin interactions. ASC also 
possesses a CARD domain which recruits pro-caspase 1 to the inflammasome complex. Self-
cleavage of pro-caspase 1 releases active caspase-1 which subsequently cleaves pro-IL-1β and 
pro-IL-18 into their mature forms for secretion from the cell. Both IL-1β and IL-18 are 
proinflammatory and they play crucial roles in host defence against pathogens. IL-1β is 
responsible for the generation of systemic and local immune responses by causing fever, 
activating lymphocytes and recruiting them along with neutrophils to the site of infection. IL-
18 lacks the pyrogenic nature of IL-1β but is involved in induction of IFN-γ production by T-
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cells and NK cells to drive T-helper cell type 1 (Th1) responses during adaptive immunity 
development. The NLRC4 inflammasome can activate caspase-1 in an ASC-dependent and –
independent manner. Pro-IL-1β and pro-IL-18 are both expressed in an NFκB dependent 
manner. Hence their cellular levels are increased by TLR and NLR activation. The 
inflammasome can then be activated in response to a diverse selection of ligands, increasing 
the levels of IL-1β and IL-18 and amplifying the initial response to many PAMPs. 
 
Fig. 4. Simplified representation of NLR family member signalling. Ligands are coloured 
blue, receptors are red, adaptor proteins purple, pro-inflammatory transcription factors 
green, and cellular outputs orange. Caspase-1 activation ultimately results in cell death 
through the process of pyroptosis. 
2.3 Retinoic acid-inducible gene I-like receptors (RLRs) 
RLRs are a small family of PRRs that detect intracellular RNA. RLRs use CARDs to interact 
with downstream signalling components. Activation results in expression of type I IFNs and 
other pro-inflammatory cytokines. In conjunction with endosomal TLRs the RLRs provide a 
robust antiviral response. RIG-I recognises short uncapped dsRNA or ssRNA, whereas 
melanoma differentiation-associated 5 (MDA5) detects longer dsRNA such as poly (I:C). 
Both proteins signal by forming CARD:CARD interactions with MAVS (mitochondrial 
antiviral signalling protein; also known as IFN-β-promoter stimulator 1 (IPS-1)) which is 
localised on the exterior membrane of the mitochondria. This activates the IRF transcription 
factors, but again leads to co-stimulation of the MAP kinase pathway as seen in the 
signalling of the other PRRs. The RLRs are also involved in sensing and triggering a 
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response to cytoplasmic DNAs which can be transcribed by RNA polymerase III into 
dsRNA. 
2.4 C-type lectin receptors (CLRs) 
CLRs are characterised by the presence of a C-type lectin domain. Over 1000 proteins in the 
human genome could be described as CLRs, however, only a few specifically modulate the 
innate immune response. CLRs are involved in diverse, often regulatory, roles within the 
immune system, such as antigen presentation and phagocytosis. Dectin-1 and dectin-2 are 
the best characterised CLRs and signal through their immunoreceptor tyrosine-based 
activation motif (ITAM). The ITAM domain activates the spleen tyrosine kinase (Syk) which 
upregulates many of the pathways triggered by the other PRRs. 
2.5 Summary 
It is clear that although there is much diversity in the range of PAMPs that can be detected 
by PRRs, there is a common signalling strategy geared towards causing inflammation to 
both contain and then remove the infection. The mechanism of activation and signalling 
cascades involved in this process are highly complex and contain a significant level of 
overlap, redundancy and cross-talk. A more comprehensive discussion of these processes 
can be found in a variety of excellent review articles and the references they contain (Davis 
et al., 2011; Kawai and Akira, 2011; Loo and Gale, 2011; Osorio and Reis e Sousa, 2011).In the 
following sections we will see that although pathogens usually activate a number of PRRs, 
they have adapted their modes of attack so as to bypass the innate immune system, and 
hence be able to colonise the body. 
3. Pattern recognition receptor responses to pathogens 
The previous section highlighted the diversity of PRRs available to respond to PAMPs. To 
demonstrate the importance of PRRs in the response to infectious diseases we have chosen 
four major pathogens; the bacteria Salmonella spp., the virus Influenza A, the fungi Candida 
albicans, and the parasite Schistosoma mansoni. Here we describe the importance of PRRs in 
the recognition of these pathogens and induction of an innate immune response against 
them. As will become apparent the innate immune system has evolved so that multiple 
PRRs recognise different PAMPs from the same pathogen.  
Pathogens, like higher organisms, also undergo evolutionary pressure to survive. In essence 
this can be viewed as a host-pathogen arms race. Successful pathogens are able to evade, limit, 
or manipulate detection by PRRs, and in some cases, utilise PRR signalling pathways for their 
own benefit. Pathogen survival can be augmented in a number of ways. These include 
targeting the recognition receptor, the signalling transduction event, and the key effector 
proteins of the innate immune system (Hajishengallis and Lambris, 2011). The innate immune 
system is a common target for immune evasion strategies for two primary reasons. Firstly, it is 
the initial host defence encountered by the pathogens upon infection. Secondly, the innate 
immune system is essential for the development of adaptive immunity. Consequently, by 
exploiting the innate immune system, pathogens can undermine the whole immune response 
of the host. Many different mechanisms are employed by pathogens to subvert immune 
signalling. These include: the use of immunomodulatory proteins; receptor antagonists; the 
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induction of immunosuppression; activation of host immune inhibitory receptors; reduced 
expression, or alteration, of the PAMP; and manipulation of PRR crosstalk. In short successful 
pathogens are able to survive for longer in, and colonise, the host through maintenance of a 
careful balance between innate immune activation and suppression. In addition to identifying 
the key PRR-pathogen interactions we will provide examples highlighting the ability of these 
organisms to survive in the host and evade the innate immune response. 
3.1 PRRs and Salmonella 
3.1.1 Salmonella is a Gram-negative bacterium that causes food-borne diseases 
Salmonella is a Gram-negative (Figure 5), rod-shaped, flagellated, bacterium which invades, 
and replicates and survives within, immune cells such as macrophages (Coburn et al., 2007). 
There are over 2500 serotypes of Salmonella enterica. S. enterica typhi and S. enterica 
typhimurium cause typhoid fever and enterocolitis respectively in humans. These diseases 
affect millions of people globally causing around 600,000 deaths annually, mostly in infants 
and immunocompromised patients. 
Salmonella is transmitted via the faeco-oral route following ingestion of contaminated food, 
water or animal products, or close contact with an infected individual. Infection 
predominantly occurs in the epithelial lining of the intestine with intestinal epithelial cells 
(IECs) and macrophages being key cells for both bacterial uptake and immunity. IECs act 
not only as physical barriers to infection, but also contribute to the innate immune response 
following PRR activation. Bacterial uptake by macrophages (and dendritic cells) results in 
stimulation of a wide range of PRRs and can also serve as a route to systemic infection. The 
pathophysiology of Salmonella infections is strongly connected to the strong inflammatory 
response from the host. Interaction between host PRRs and Salmonella virulence factors 
influence the pathology, morbidity, and mortality at different stages of infection.  
 
                  Gram-negative bacteria         Gram-positive bacteria 
Fig. 5. Schematic of the cell wall structure of Gram-negative (left-hand image) and Gram-
positive (right-hand image) bacteria highlighting the key components of each type of 
bacterial wall. Salmonella is a rod-shaped Gram-negative bacterium. Two key PAMPs 
associated with Salmonella are LPS and lipopeptide which activate TLR4 and TLR2 
respectively. In addition, the surface of Salmonella possesses flagella, another potent 
immunostimulatory molecule. 
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3.1.2 Salmonella PAMPs and PRR activation 
Salmonella is recognised by a wide range of PRRs: TLR1, 2, 4, 5, 6, and 9; NLRC4; NLRP3; 
NOD1 and NOD2 (Hold et. al., 2011). Of these the key PRRs are TLR2, TLR4, TLR5 and 
NLRC4. Cell culture studies and mouse models have identified several Salmonella PAMPs 
responsible for PRR activation. Of particular importance are LPS, lipoproteins and flagellin 
(Figure 5). Flagellin provides an interesting example of a ligand that is able to activate two 
distinct receptors (TLR5 and NLRC4) leading to distinct immune responses (Franchi et al., 
2006; Hayashi et al., 2001).  
LPS and lipoproteins lead to classical activation of TLR4 and TLR2 signalling pathways 
respectively (Section 2.1). The importance of TLR2 signalling is influenced by the severity of 
infection, playing a key role at high multiplicities of infection. In contrast, the role of TLR4 
appears essential at all levels of Salmonella infection (Spiller et al., 2008; Talbot et al., 2009). 
TLR4 activation by LPS requires several co-receptors such as: myeloid-differentiation 2 
(MD2), cluster of differentiation 14 (CD14), and LPS-binding protein (LBP). The TLR4 
signalling pathway is different from all other TLRs as its activation results in two separate 
signalling cascades: MyD88-dependent and MyD88-independent pathways which result in 
NF-κB activation and IFN-β and NFB activation respectively (Figure 3). This activation is 
regulated temporally and spatially as it is been suggested that MyD88-dependent signalling 
occurs first on the plasma membrane, following which the receptor complex is endocytosed 
after which it will sequentially activate the MyD88-independent pathway. This is a classic 
example of the use of subcellular localisation of the receptor signalling complex to 
determine use of downstream adaptor proteins and the specifics of the signalling pathway 
activated. The importance of TLR4 in the response to Salmonella is highlighted by 
observations that mice possessing defects in TLR4 are incapable of mounting a normal 
immune response to Salmonella typhimurium infection (Talbot et al., 2009). It appears that the 
relative importance of different TLR and adaptor proteins in combating Salmonella is 
dependent upon the bacterial load. For example, the adaptor protein Mal only appears 
important at low multiplicities of infection (Kenny et al., 2009). This may well be a deliberate 
ploy on the part of the host to manage the severity of the response at a level which reflects 
the severity of infection.  
TLR5 recognises monomeric flagellin. TLR5 is expressed on the basolateral surface, not the 
apical surface, of polarised epithelial cells so only responds to flagellin that has breached the 
epithelial barrier. This is likely to be a host strategy to stop inappropriate immune activation 
by flagellated commensal bacteria in the lumen (Gewirtz et al., 2001; Hayashi et al., 2001) . 
Once the bacterium has breached the epithelial barrier flagellin can then be detected by the 
baso-laterally located receptor. In addition, TLR5 is found expressed on the surface of 
immune cells such as macrophages and DCs. 
The mechanism of flagellin recognition by TLR5 is interesting as only monomeric flagellin is 
recognised. This is because the TLR5 binding site is buried in the functional flagellar 
filament. This is one of the bacterium’s ways of evading the host immune system. A single 
filamentous flagella consists of 11 protofilaments, each of which contains four globular 
domains (D0-D3) (Figure 6). The recognition site for TLR5 is contained in the N-terminal D1 
domain. This region is essential for motility and is consequently highly conserved (Smith et 
al., 2003). Mutations within D1 have been shown to abolish recognition by TLR5, bacterial 
motility, and to disrupt protofilament assembly. In particular differences in amino acids 89-
 
Pattern Recognition Receptors and Infectious Diseases 393 
96 have been implicated in the ability of some species of bacteria to evade immune detection 
by TLR5 (Andersen-Nissen et al., 2005). 
 
Fig. 6. Crystal structure of FliC flagellin from S. typhimurium (pdb entry 1io1). Domain 
colouring is: D1 – light purple; D2 – blue; D3 – green; the yellow region in D1 corresponds to 
amino acids 89-96.  
Prior to detection by TLR5, flagella has to be depolymerised into its monomeric form. Direct 
contact between the bacterium and the host cell triggers the de novo synthesis and secretion 
of monomeric flagellin into the host cell via T3SS (Subramanian and Qadri, 2006). This 
process is triggered by the bacterium sensing lysophospholipids produced by the host cells 
upon infection and is important for initial inflammatory and innate immune responses by 
IECs. Following activation TLR5 forms a homodimer and initiates MyD88-dependent 
signalling cascades (Figure 3) as part of the innate immune response. One effect of this is to 
recruit neutrophils and macrophages to the site of infection.  
Once Salmonella has breached the epithelia it can be phagocytosed by macrophages. The 
bacterium can reside and replicate inside a Salmonella-containing vesicle. Fragments of 
flagellin enter into the cytoplasm, probably via a type III secretion system, from where it 
stimulates the NLR family receptor NLRC4 (Franchi et al., 2006). NLRC4 is also activated by 
the protein PrgJ, a component of the type III secretion system expressed by the Salmonella 
pathogenicity island (SPI)-1 (Miao et al., 2010). The mechanisms of NLRC4 activation by 
bacteria such as Salmonella are complex and seem to follow some form of temporal cascade. 
The net effect is that activation of NLRC4 leads to inflammasome formation, caspase-1 
activation and secretion of IL-1 and IL-18. In addition, caspase-1 activation via NLRC4 can 
trigger macrophage death through pyroptosis. Pyroptosis is a caspase-1 dependent, 
programmed cell death event that has features of both apoptosis and necrosis. The process 
of pyroptosis results in the release of pro-inflammatory cellular contents and also serves to 
limit intracellular bacterial replication (Roy and Zamboni, 2006) (Figure 4).  
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3.1.3 Modulation of the innate immune response by Salmonella 
Salmonella is capable of infecting, surviving, and multiplying within macrophages. This 
requires multiple virulence proteins which are predominantly encoded on the SPI-2 
pathogenicity island. These factors enable the bacterium to resist the oxidative burst and 
maturation of phagosomes and lysosomes. In fact the bacterium modifies these endocytic 
vacuoles and generates an environment conducive to bacterial replication – the salmonella 
containing vacuole (SCV) (Figure 7).  
In addition to acting as a trigger of NLRC4 signalling (Section 3.1.2) the T3SS allows proteins 
to be injected into the cell cytoplasm that modulate cellular function. A major role of these 
proteins is to alter cytoskeletal function and permit bacterial entry. In addition, Salmonella 
also secretes an immunomodulatory protein SipB. The precise role and mechanism of action 
of SipB is unknown. However, the protein is capable of interacting with caspase-1 and 
consequently altering the signalling pathways involved in caspase-1 activation and 
downstream functionality (Hersh et al., 1999). Other bacteria also produce proteins that 
modulate immune signalling. For example, it has recently been shown that Escherichia coli 
and Brucella melitensis produce TIR domain containing virulence factors that inhibit TLR 
signalling by directly blocking MyD88 adaptor protein function through a homotypic TIR-
TIR interaction (Cirl et al., 2008). 
 
 
 
 
Fig. 7. Formation of a Salmonella containing vacuole (SCV) promotes Salmonella survival and 
virulence inside host macrophages. SCV formation appears to be dependent on functional 
TLR signalling and requires acidification to activate expression of the Salmonella pro-
survival genes. 
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3.1.4 Altering PAMP properties as a way to evade immune detection 
Salmonella flagellin is a readily available and common target recognised by both 
extracellular, TLR5, and intracellular, NLRC4, PRRs. Although many PAMPs cannot be 
altered and changed in order to evade the immune response this is not the case for flagellin. 
Salmonella has been found to downregulate flagellin expression once it is inside 
macrophages, although how quickly this happens is unclear. A loss of flagellin expression 
will obviously reduce the potential for immune stimulation, but it has yet to be determined 
whether this occurs in a timeframe that will influence PRR activation. As TLR5 recognises 
monomeric flagellin mechanisms that increase flagellum stability and reduce the release of 
monomeric subunits will also reduce immune activation. 
Some other flagellated bacteria have adopted a mechanism in which they express flagellin 
lacking the proinflammatory regions found in Salmonella FliC (Section 3.1.2). The classic 
example is Helicobacter Pylori. H.pylori express the flagellin proteins FlaA and FlaB. These 
subunits retain the ability to assemble motile flagella, but lack the TLR5 stimulatory regions. 
This was elegantly demonstrated by experiments in which the comparable sequence from 
H.pylori flagellin was substituted into Salmonella FliC. The mutant flagellin lost the ability to 
activate TLR5.  
3.2 PRRs and viral PAMPs 
Viruses are more abundant than bacteria; they are also very diverse genetically and evolve 
rapidly. Viruses are obligate parasites and can only survive and replicate inside host cells. 
They have different virulence components and simpler structural features in comparison to 
bacteria. The requirement on the host cell for replication makes viral nucleic acids the key 
viral PAMPs. Consequently, only a subset of PRRs can detect them. These include: NLRP3; 
NOD2; TLR3, 7, 8, and 9; and the RIG-I like receptors (Kanneganti, 2010; Perry et al., 2005) 
(Table 2).  
 
PAMP PRR Adapter Cytokines 
Toll-like receptors (TLRs) 
dsRNA TLR3 TRIF IFN-/ pro-inflammatory 
G/U rich ssRNA TLR7 MyD88 IFN-/ pro-inflammatory 
G/U rich ssRNA TLR8 MyD88 IFN- 
unmethylated CpG DNA motifs TLR9 MyD88 IFN-  
Nod-like receptors (NLRs) 
ssRNA NOD2 MAVS Type I IFNs 
Viral RNA NLRP3 ASC IL-1/IL-18 
Retinoic acid-inducible gene I-like receptors (RLRs) 
5’ triphosphate ssRNA RIG-I MAVS/ASC/CARD9 Type-I IFNs/ IL-1 
Table 2. Natural viral PAMPs are recognised by PRRs and stimulate cytokine production. 
Viral nucleic acids generally differ from host nucleic acids through the presence of specific 
motifs and also their subcellular localisation. Viral nucleic acid (blue column) is recognised 
by specific PRRs (pink column) and this leads to receptor activation. The activated receptor 
recruits specific adaptor proteins and initiates signalling cascades. The net result of this is 
the secretion of cytokines. 
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The host response to viral infection results in the production of anti-viral agents such as type 
I IFNs that interfere with viral replication and survival inside host cells, and pro-
inflammatory cytokines such as IL-1β and IL-18. Type I IFNs are the key players in innate 
immune response against viral infection. We will expand the discussion on role of PRRs in 
viral infection by considering the example of influenza virus. 
3.2.1 Recognition of influenza by TLRs 
Influenza is a negative-sense ssRNA virus that causes pulmonary inflammation and chronic 
lung diseases. The symptoms vary from fever and inflammation to death, depending on the 
strain of the virus and the host response. Influenza enters host cells by endocytosis 
following recognition of sialic acid residues by the viral haemagglutinin protein. This is 
followed by pH-dependent fusion of the viral and endosomal membranes allowing release 
of the viral core into the cytosol. The exact sequence of events that subsequently leads to 
recognition of influenza by PRRs is still largely unknown. Influenza PAMPs can be 
recognised by a variety of PRRs (Figure 8 and Table 2). However, the majority of 
immunopathology appears to result from TLR7, NLRP3 and RIG-I activation (Ichinohe, 
2010). Plasmacytoid dendritic cells (pDCs) are the major cell-type responsible for mounting 
an immune response to influenza through the secretion of high amounts of type I IFNs and 
proinflammatory cytokines (Perry et al., 2005). Macrophages, nasal airway epithelial cells 
and monocytes have also been found to respond to influenza. Secreted type I IFNs interact 
with IFN receptors causing expression of type I IFN-stimulated genes with antiviral 
properties. For example, increased expression of RIG-I like receptors and proteins involved 
in the inhibition of viral transcription and trafficking. Type I IFNs also influence the 
development of adaptive immunity such as increasing expression of costimulatory 
molecules on macrophages and DCs, aiding maturation of DCs, and the activation of T and 
NK cells.  
pDCs are professional antigen presenting cells. Following endocytic uptake of virus 
particles the virus is degraded and can contact endosomal PRRs. The presence of ssRNA in 
the endosome activates TLR7 (Lund et al., 2004) which signals in a MyD88-dependent 
manner to activate IRF3 and IRF7 transcription factors for the expression of type I IFNs. 
ssRNA recognition by TLR7 appears to require endosomal acidification before the receptor 
can form a homodimer and initiate the signalling pathways. TLR7 and MyD88 are both 
required for the type I IFN response to influenza ssRNA in pDCs. Studies have shown that 
mice deficient in either TLR7 or MyD88 are unable to respond to influenza virus (Diebold et 
al., 2004; Lund et al., 2004). TLR7 is also expressed in other cell types such as macrophages 
and conventional DCs, however TLR7 activation in these cell types only result in expression 
of proinflammatory cytokines. This difference is due to different signalling adaptor proteins 
present in these different cell types. Human naïve B cells and effector memory CD4+ T cells 
also express and signal through TLR7 activation (Wang et al., 2006).  
The TLR7 response to influenza ssRNA is independent of viral replication. In contrast, there 
is evidence that dsRNA can induce type I IFN production via a TLR7- and MyD88-
independent pathway that requires viral replication (Guillot et al., 2005). Even though 
influenza is a ssRNA virus, dsRNA molecules are synthesised during the replicative stage of 
the virus. Certainly TLR3 recognises endosomal dsRNA from influenza virus (Guillot et al., 
2005). The downstream signalling proceeds not through MyD88, but the adaptor TRIF to 
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activate IRF3 and late-phase NF-κB. The importance of dsRNA recognition in influenza 
infection is supported by the observation that the influenza protein NS1, which sequesters 
viral dsRNA, inhibits type I IFN induction upon viral infection (Lu et al., 1995). 
 
Fig. 8. Cytoplasmic and endosomal PRRs that recognise PAMPs from ssRNA virus such as 
influenza. Different PRRs can activate different pathways, and some pathways are shared by 
several PRRs.  
3.2.2 Recognition of influenza by NLR and RLRs 
Influenza can be recognised by the NLRP3 inflammasome, RIG-I and potentially NOD2 
(Kanneganti, 2010). Activation of these signalling pathways results in the activation of 
caspase-1, IL-1 and IL-18; the production of inflammatory cytokines; and the secretion of 
type I IFNs via MAVS engagement. Each of these receptors is located in the cytoplasm 
and hence responds to the presence of RNA, 5’-phosphate ssRNA, or ssRNA within the 
cytoplasm. This contrasts to TLR7 which responds to ssRNA in the endosomal 
compartment. In the case of NLRP3 it is unknown whether viral RNA is a directly 
activating ligand for the receptor. Indeed it is more likely in this instance that the presence 
of viral RNA in the cytoplasm leads to a homeostatic disruption that in turn activates 
NLRP3, stimulates inflammasome formation, and initiates a protective innate immune 
response. 
NOD2 and NLRP3 elicit different immune responses to viral RNA (Fig. 6). NLRP3 
stimulation leads to activation of caspase 1 and subsequent processing of the pro forms of 
IL-1β and IL-18 via inflammasome formation. Both IL-1 and IL-18 are important in the 
clearance of influenza infection as mice which lack the IL-1 receptor and consequently can’t 
respond to these cytokines show impaired viral clearance and increased mortality (Schmitz 
et al., 2005). Unlike NLRP3, NOD2 does not form an inflammasome. The primary role of 
NOD2 seems to be the detection of the bacterial peptidoglycan fragment muramyl dipeptide 
and signalling through NF-κB regulated pathways. However, more recently NOD2 has been 
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reported to respond to viral ssRNA (Sabbah et al., 2009). Viral ssRNA results in activation of 
an alternative MAVS-dependent NOD2 signalling cascade in which NOD2 relocalises to the 
mitochondria and ultimately activates IRF3. This leads to the induction of an antiviral type I 
IFN response. A loss of NOD2 led to an increase in the susceptibility of mice to influenza 
infection, a reduction in IRF3 phosphorylation and a diminishment of the type I IFN 
response (Sabbah et al., 2009). 
RIG-I can also signal in a MAVS-dependent manner to generate a type I IFN response 
(Kanneganti, 2010). Interestingly RIG-I has also been reported to stimulate the production of 
pro-IL-1 production in a MAVS-CARD9-NFkB dependent manner; as well as inducing pro-
IL-1 processing and secretion in an ASC-dependent inflammasome manner (Kanneganti, 
2010; Pichlmair et al., 2006). This therefore provides a single receptor example of cross-talk 
along multiple signalling pathways in order to maximise the anti-viral and inflammatory 
reponse.  
3.2.3 Subversion of the innate immune response by influenza 
Viruses have long been known to utilise multiple strategies to evade the immune response, 
persist in the host, or allow reinfection. In the case of influenza virus the influence of 
antigenic drift in the surface haemaglutinin and neurominidase proteins allows evasion of 
the adaptive antibody response thereby limiting the protective effects of vaccination and 
facilitating influenza epidemics. Antigenic shift is a more extreme, and less common, 
evasion strategy in which viruses from different species undergo recombination to create a 
new potentially pandemic viral strain. Commonly recombination occurs between human 
and avian viral strains.  
Influenza virus also employs various strategies to disrupt the innate immune response; 
either by interfering with PRR mediated detection of viral components, or through 
modulation of signalling cascades. The viral non-structural protein (NS)1 is a good example 
of a protein that targets a specific signalling pathways to avoid detection. NS1 has the 
potential to inhibit the activation of caspase 1 and the production of type I IFNs. 
Interestingly there does appear to be strain-dependent variation in activity of NS1 in this 
respect. The N-terminal region of NS1 appears to be important for the inhibition of 
inflammasome-dependent immune responses; specifically through inhibition of caspase-1 
activation, and hence IL-1β and IL-18 production (Kanneganti, 2010). NS1 has also been 
reported to inhibit RIG-I-MAVS-dependent antiviral signalling (Bowie and Unterholzner, 
2008). Pichlmair and colleagues, reported that NS1 binds directly to RIG-I and inhibits its 
activation, thereby reducing type I IFN production (Pichlmair et al., 2006). However, the 
exact molecular mechanism of how NS1 inhibits RIG-I signalling is not clear. This 
interaction may directly antagonise RIG-I function, or it could involve other proteins that 
are required for proper signalling. For example, NS1 also sequesters dsRNA so that they 
cannot be detected by dsRNA-recognising PRRs such as TLR3 and PKR. More recently, 
Gack and co-workers showed that NS1 inhibits RIG-I signalling by inhibiting activation of 
ubiquitin ligase tripartite motif (TRIM)25; a crucial component of the RIG-I signalling 
cascade required for activation of RIG-I through ubiquitination within the CARD domain 
(Gack et al., 2007).  
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3.3 PRRs and Candida albicans 
3.3.1 Candida albicans 
The yeast Candida albicans is a common human commensal that colonises mucocutaneous 
surfaces of the oral cavity, gastrointestinal tract and vagina. Candida albicans is often a 
benign member of the mucosal flora. However, under specific host conditions, such as a 
change in immune status or commensal species, Candida albicans can proliferate in a 
saprophytic state and become an opportunistic pathogen. This usually results in mucosal 
diseases, but on occasion the infection may become systemic and life-threatening. A specific 
example is nosocomial candidiasis in hospital patients with a compromised immune system. 
Candida albicans can differentiate in yeast, pseudohyphal and hyphal forms. The hyphal 
form is often linked to disease as it facilitates infection of epithelial cells and tissue damage. 
In addition to hyphae Candida species enhance their pathogenicity through biofilm 
formation and secretion of proteases and toxins. The balance between the commensal and 
pathogenic state is what makes Candida albicans a useful study case for looking at the 
interplay between host PRRs and PAMPs, and the dynamics that lead to 
protection/tolerance or infection.  
3.3.2 Induction of an immune response by Candida albicans 
It is hypothesised that the initial interaction between the host immune cell and specific 
C.albicans PAMPs is critical for deciding whether the immune response is protective or 
invasive. Studies suggest that a prolonged anti-inflammatory response against C. albicans, 
including increased production of IL-10, IL-4 and differentiation of regulatory/suppressive 
T cell subsets facilitates invasion and the initial development of disease. In the absence of IL-
10 there is a switch to a protective response by the innate immune system. This includes 
stimulation of inflammatory cytokines such as IL-12, TNFα, and IL-6; and progression 
towards a Th17 response leading to IL-17 and IL-22 production to clear the infection. 
Further evidence for the role of IL-10 as a modulator of yeast infection is suggested by 
animal models. IL-10 deficient mice are protected against the toxic effects of C.albicans 
infection and show a decline in inflammatory markers associated with yeast infections. In 
contrast, inclusion of IL-4 and IL-10 in a gastrointestinal model of yeast infection facilitates 
invasion rather than protection. 
Interaction studies between host immune cells and Candida albicans have identified various 
PRRs that recognise yeast derived PAMPs, and facilitate protective responses via the pro-
inflammatory pathway. Most yeast and fungal PAMPs have been identified in the cell wall, 
a complex matrix consisting of glucans, mannans, mannoproteins and glycolipids. Several 
receptors including TLR4 and the C-type lectins Dectin-2, Mincle and the macrophage 
mannose receptor bind to mannans of Candida species. Dectin-1, lactosylceramide 
complement receptor-3 and scavenger receptors recognise β-glucans of Candida.  
3.3.3 TLR sensing of Candida albicans 
TLRs are involved in the immune response against C. albicans as well as other fungal agents, 
particularly TLR2 and to a lesser extent TLR4. Both pathogenic and commensal forms of C. 
albicans are involved in TLR-dependent signalling, in addition to other commensal yeasts 
such as Saccromyces cerevisiae. TLR2 recognises phospholipomannan components of the 
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fungal cell wall. TLR4 is activated by α-mannans on C. albicans and initiates the production 
of IL-12 by host immune cells and a subsequent protective Th1 response. TLR4 
polymorphisms Asp299Gly/Thr399Ile are associated with an increased susceptibility to C. 
albicans infection in the bloodstream, with an increase in IL-10 levels being the contributing 
factor (Van der Graaf et al., 2006). In addition to a pro-inflammatory response, TLR2 
activation may also lead to the production of IL-10 and generation of T regulatory cells and 
a non-protective Th2 response. This is supported by data on TLR2 KO mice which are more 
resistant to Candida infection. The TLR2 polymorphism R753G gives rise to patients with 
enhanced Candida sepsis, suggesting that TLR2 is an important PRR for regulation of 
Candida infections (Woehrle et al., 2008). Indeed, TLR2 signalling complexes may modulate 
the Th1/Th2 (IL-10) balance in response to fungi by switching between pro- and anti-
inflammatory responses. TLR signalling occurs in crosstalk with the carbohydrate specific 
PRRs, the C-type and S-type lectins, to regulate C. albicans infection.  
3.3.4 CLR recognition of Candida albicans 
CLRs such as Dectin-1, Dectin-2, Mincle, DC-SIGN (SIGNR1, mouse homolog) and mannose 
receptor (MR) are key PRRs in the immune response against fungi.  The interaction of CLRs 
with PAMPs is mediated via carbohydrate recognition domains (CRD), which facilitate 
internalisation, degradation and antigenic presentation. CLRs signal via the Syk pathway to 
initiate an inflammatory response using an ITAM motif in their cytoplasmic tail. Some CLRs 
such as Dectin-2, lack an ITAM motif and instead utilise adaptor molecules such as the Fc 
receptor γ chain and the DNAX-activating protein (DAP12) which have an ITAM motif for 
signalling. 
Dectin-1, which is expressed in neutrophils, macrophages and DCs, is a specific receptor for 
β-1,3 glucans, located in the cell walls of fungi, such as Saccharomyces cerevisiae (zymosan) 
and Candida albicans. Dectin-1 signalling pathways are not completely understood. It is 
proposed that Dectin-1 mediated responses may require crosstalk with TLRs, NLRs, 
tetraspanins and the DC-SIGN receptor. Dectin-1 binds and internalises β-glucans, and 
mediates its own signalling pathway which includes the production of reactive oxygen 
species (ROS) also termed an oxidative burst, activation of NFκβ and secretion of 
proinflammatory cytokines. Following ligand recognition via the CRD, Dectin-1 is 
phosphorylated by the tyrosine kinase Src, which recruits Syk to the ITAM motif to activate 
MAPKs and NFAT. This Syk interaction also mediates formation of the CARD9-Bcl10-Malt1 
complex, which stimulates NFκβ and the secretion of proinflammatory cytokines. This 
ultimately leads to a Th17 T cell response. Th17 cells are particularly important for anti-
microbial immunity at the epithelial and mucosal barriers and produce cytokines such as IL-
17 and IL-22 which stimulate anti-microbial proteins. A lack of Th17 cells leaves the host 
susceptible to invasion by opportunistic pathogens such as C.albicans.  
A recent study suggests that Malt-1 activation of the NFκβ subunit C-Rel is important for 
induction of Th17 enhancing cytokines IL1β and IL23. It was also evident that Dectin-1 
activates all components of the NFκβ complex, whereas Dectin-2 specifically activates C-Rel 
(Gringhuis et al., 2011). Recent studies suggest that Dectin-1 NFκβ activation is induced by 
zymosan, whereas hyphal forms of C.albicans activate NFκβ via Dectin-2. Hyphae 
stimulation in C.albicans also facilitates association of CARD-9 with Bcl10, in a Dectin-2 
specific manner (Bi et al., 2010). This is a good example of how different PRRs of the host 
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have distinguished between pathogenic (hyphae producing) and commensal forms of 
Candida albicans. 
The ability of Dectin-1 to activate Th17 responses assists in the prevention of fungal 
infection. Loss of Dectin-1 in KO mice and Dectin-1 polymorphisms in humans makes the 
host more susceptible to infection (Ferwerda et al., 2009b). In C.albicans infection, β-glucans 
may also stimulate Th17 and regulatory T cell responses via a Dectin-1/TLR2 crosstalk, in 
addition to the Dectin-1 specific pro-inflammatory cytokine response (Gantner et al., 2003; 
LeibundGut-Landmann et al., 2007). This Dectin-1/TLR2 response also involves the 
production of prostaglandin E2, which upregulates Th17 dependent cytokines IL-6 and IL-
23 (Smeekens et al., 2010). Dectin-1 also synergises with TLR2 and TLR4 for the production 
of TNFα and there is evidence to suggest that Dectin-1 and TLR2/6 pathways crosstalk to 
enhance responses by each receptor. Furthermore, Dectin-1 activation also upregulates pro-
IL-1 for subsequent activation by the NLRP3 inflammasome (Cheng et al., 2011).      
Dectin-1 also associates with Galectin-3, an S-type lectin that binds to β-1,2 mannosides 
present in the cell wall of Candida albicans, an interaction that is required for 
proinflammatory responses in fungi. The Dectin1-Galectin-3 complex modulates TNFα 
levels, whereby a decrease in galectin-3 corresponds to a decrease in TNFα. Mutant 
C.albicans expressing more β-glucan on the cell wall surface had reduced galectin-3 binding 
and a reduction in the protective pro-inflammatory response. Hence, association between 
Galectin-3 and Dectin-1 can modulate the proinflammatory response to help distinguish 
between pathogenic and nonpathogenic fungi (Esteban et al., 2011). 
Dectin-2 recognises several fungal species including C.albicans and interacts with PAMPs of 
high mannose content, specifically α-linked mannans and zymosan. Dectin-2 also activates 
NFκβ and a Th17 response via the Syk-CARD9 pathway, as well as MAPKs via a CARD9 
independent pathway. However unlike Dectin-1, it couples to Syk indirectly utilising the 
ITAM motif of the Fc receptor. A recent study has suggested that it is Dectin-2, rather than 
Dectin-1, that is more involved in the Th17 response to C.albicans and their hyphae, with IL-
1β and IL-23 induction being Dectin-2 dependent. DCs from Dectin-2 KO mice show a 
limited cytokine response to α-mannans (Saijo et al., 2010). 
Macrophage inducible C-type lectin (Mincle) binds to yeast cell wall components, 
specifically α-linked mannans, and like Dectin-2 also uses the Fc receptor to signal in a Syk-
CARD9 dependent matter. Mincle has also been linked to TLR2 responses. DC-SIGN and its 
mouse homolog (SIGNR1) recognises complex mannoside structures on the surface of yeast 
facilitating internalisation. SIGNR1 specifically binds zymosan as well as live and heat killed 
C.albicans. SIGNR1 has also been reported to modulate TLR4 dependent signalling and to 
itself induce a proinflammatory response against C.albicans (Takahara et al., 2011). SIGNR1 
may also interact with Dectin-1 to enhance Syk dependent pathways. 
There is recent evidence to suggest that the interaction of candida albicans with glucan 
(Dectin-1) and mannan (Dectin-2) specific receptors, works in combination with the adaptor 
protein MyD88 to activate phospholipase A2 and the production of eicosanoids, which are 
important modulators of inflammation (Suram et al., 2010). 
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3.4 PRRs and Schistosoma mansoni 
3.4.1 Schistosoma infection and immunity 
The parasitic worm Schistosoma represents the fourth most prevalent helminth infection 
worldwide affecting 200 million people. In schistosomiasis, the human parasitic disease 
caused by helminths, the parasite takes on various forms during its lifecycle, which presents 
a variety of PAMPs to the host and contribute to the developing host immune response. The 
lifecycle of S.mansoni in mammalian hosts begins when the larval stage (cercariae) is 
released from an intermediate host (snail; genus Biomphalaria) and then infects host cells, 
where it transforms into adult worms. Hosts infected with these parasites accumulate 
hundreds of intravascular worms which secrete various antigenic molecules into the blood 
which continuously trigger the host inflammatory response and facilitate prolonged 
colonisation. During S.mansoni infection, the adult worms can survive for many years, 
where they evade the host immune response, by establishing a balance between host 
activation and immune suppression. The adult worms also produce hundreds of eggs daily 
over a life period of 5 to 30 years. A Th2 anti-inflammatory response is triggered by the 
presence of eggs as well as soluble antigens secreted by the eggs, whereas a Th1 
inflammatory specific response is more likely when adult worms interact with host immune 
cells.  
3.4.2 Recognition of Schistosoma mansoni by PRRs 
Schistosoma mansoni produces various glycoconjugates (glycoproteins and glycolipids) that 
interact with PRRs of the innate immune system and potentially modulate the function of 
host immune cells (Figure 9). The mouse model of schistosomiasis identified that 
Schistosoma glycoconjugates containing Lacto-N-fucopentaose III (LNFPIII) induce a Th2 
response in collaboration with TLR4. Also the schistosomal tegument has been reported to 
activate inflammatory responses in DCs via a TLR4/MyD88 pathway. Schistosomiasis is 
also associated with high levels of endotoxemia and elevated levels of high mobility group 1 
(HMGB1) protein, which is a ligand for TLR2, TLR4 and the RAGE receptor. 
Lysophosphatidylserine (Lyso-PS) and dsRNA from the eggs of S.mansoni also activate 
TLR2 and TLR3 inflammation pathways respectively. Soluble schistosomal egg antigens 
(SEA) inhibit TNFα and IL-6 secretion originating from TLR signalling pathways. This TLR 
suppression occurs at the same time as NLRP3 activation and IL-1β production (Ritter et al., 
2010). SEA binds to the Dectin-2/FcRγ complex and signals via the Syk pathway to induce 
ROS and potassium efflux, known effectors of the inflammasome NLRP3. S.mansoni 
infection of mice without inflammasome components ASC and NLRP3 failed to induce an 
inflammatory response indicated by the lowered IL-1β levels and the downregulation of T 
cell responses. 
CLRs also recognise glycans associated with schistosomes using one or more CRD (Figure 
9). The CLRs DC-SIGN, macrophage galactose type lectin (MGL) and MR on human DCs, 
bind specific glycans on the SEA of S.mansoni. This binding facilitates internalisation of the 
SEA and promotion of a Th2 response. DC-SIGN can also bind to the larval form of 
S.mansoni via glycolipids. Human DCs primed with adult worm glycolipids switch towards 
a Th1 immune response and induce an inflammatory cytokine cascade. DC-SIGN binds to 
fucose components of the glycolipid of the worm and helps activate TLR4 signalling and 
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inflammation (van Stijn et al., 2010). It is proposed that DC-SIGN recruits glycolipids and 
then presents them to TLR4, via a TLR4-DC-SIGN complex in lipid rafts. 
 
Fig. 9. PRRs involved in the immune response against schistosomal PAMPs at different 
stages of the schistosomes lifecycle. The activation of a Th1 (inflammatory) and a Th2 
(humoral) response demonstrates the ability of the parasite to regulate infection. Pictures of 
schistosoma egg, larvae and adult reproduced with the permission of David Dunne. 
4. The role of PRRs in immunisation against infectious disease 
Immunisation is a crucial and highly successful defence against many infectious diseases 
including: measles, tetanus, diphtheria, rubella, polio and tuberculosis. Over recent years it 
has become apparent that PRRs play a major and crucial role in the processes of immune 
priming and polarization. These new findings have been applied to vaccine research in two 
major areas: firstly to determine the molecular mechanism of action of known vaccines and 
adjuvants; and secondly new adjuvant components have been developed that target specific 
PRRs in a quest towards rationally designed ‘customised’ vaccines. 
4.1 The role of PRRs in current vaccines 
PRRs are important for the priming of adaptive immune responses (Section 3.3). It is not 
surprising that many current vaccines also function, at least in part, by activating PRRs. 
Studies with knock-out mice have shown that PRRs are critical for the optimal function of 
several known vaccines. However, PRRs are not necessary for all vaccines to induce 
protective immune responses, and several vaccines instead trigger alternative pro-
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inflammatory pathways that appear to primarily recognize tissue or cellular injury rather 
than PAMPs. 
Although much is known about the PAMP content of many vaccines, the role of PRRs in 
triggering protective immunity is more challenging to determine for three reasons. Firstly, 
individual PAMPs can be efficiently identified by measuring innate activation of cells such 
as DC in vitro whereas induction of immunity can only be measured in vivo with 
corresponding increase in cost and difficulty of interpretation. Secondly, the presence of 
multiple PAMPs and corresponding PRRs that coordinate host responses means that study 
of immunity in single knockouts often leads to partial phenotypes. Thirdly, many important 
human vaccines- particularly live attenuated vaccines – show host-species specific activity, 
preventing the direct study in PRR knockout mice.  
4.1.1 Evidence of PAMP content and PRR activation by traditional vaccines  
Traditionally, vaccines belong to one of three types: live attenuated vaccines, such as the 
eponymous vaccinia, are infectious agents in their own right, and prime protective immunity 
but lack pathogenicity; inactivated vaccines contain whole infectious agents that have been 
inactivated – for example by heat or chemical sterilization – to prevent infection, but still 
provoke protective immunity without replication; subunit vaccines contain a purified 
protective antigen combined with an adjuvant i.e. a formulation that promotes an immune 
response against the subunit. Of these three types, it is clear that both live attenuated and 
inactivated vaccines closely resemble pathogens – and therefore contain many PAMPs and 
trigger multiple PRRs. Subunit vaccines, in contrast, only contain PAMPs if they are co-
purified with the antigenic subunit, if the antigenic subunit is itself PRR agonistic, or if the 
adjuvant activates PRRs (see 4.1.2, 4.1.3 and 4.1.4). 
4.1.2 PRR activation by live attenuated vaccines 
Our oldest vaccines are live attenuated pathogens. Yet they are also the most poorly 
understood due to the complex interplay between parasite and host. Live attenuated 
vaccines contain a plethora of PAMPs. For example, live attenuated bacterial vaccines such 
as Mycobacterium tuberculosis BCG and live oral Typhoid Fever vaccine are rich in well 
known PAMPs such as bacterial DNA, lipopolysaccharides and lipopeptides. Two major 
challenges in characterizing PRR triggering by live attenuated viral vaccines are the fact that 
PAMP content and location changes during the infectious cycle (e.g. production of different 
types of nucleic acids, viral entry into host cells); and the presence of PRR inhibitors can 
obscure signaling.  
Vaccinia is one of the best studied live attenuated vaccines. The importance of PRRs in 
vaccinia virus sensing became clear very early on with the discovery that its genome 
encodes inhibitors of IL-1 and TLR signaling (Bowie et al., 2000). Host responses to vaccinia 
are complex. Pathways act separately and synergistically, and there are diverse responses 
from different cell types. Studies of viral-induced cytokine production from cells from 
knockout mice have started to unpick this complexity and demonstrated that vaccinia can 
trigger multiple PRR including TLR2/TLR6, (Delaloye et al., 2009; Zhu et al., 2007), the RLR 
MDA-5 (Delaloye et al., 2009), and TLR8 (Martinez et al., 2010). The inflammasome 
component NALP3 is also required for maximal cytokine responses (Delaloye et al., 2009).  
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Although the rich PAMP content of live attenuated vaccines has been characterised, 
understanding fully how PRR triggering induces protective adaptive immunity still remains 
a challenge. For example, MyD88-/- mice show reduced protection from experimental 
tuberculosis after vaccination with BCG (Fremond et al., 2004). And studies of the mouse 
Typhoid model Salmonella typhimurium suggest that TLRs and MyD88 are required in a 
range of cell types for optimal function of oral live attenuated bacterial vaccines (Dougan et 
al., 2011). Likewise, although the precise PRR requirement for protective immunity to 
vaccinia cannot be determined due to the lack of appropriate (or safe) models, TLR2 and 
MyD88 knockout mice do show partial reduction in MVA-specific T cell responses and 
CD8+ T cell IFN secretion (Zhu et al., 2007).  
4.1.3 PRR activation by inactivated vaccines 
Inactivated vaccines are generally simpler to study because they have a fixed content, do not 
undergo metabolic changes, and in general do not subvert host signaling. Furthermore, a 
great deal is known about the PAMP content of inactivated organisms since killed microbes 
have been of great use for decades as a source of ‘natural’ PAMPs in the identification and 
study of PRRs.  
Recently, a major pathway for viral nucleic acid recognition – viral ssRNA triggering TLR7 – 
was initially identified by study of IFN production by pDC in response to heat-inactivated 
influenza virus (Diebold et al., 2004) (Section 3.2.1). Indeed, in the absence of TLR7 whole 
inactivated influenza virus vaccine loses immunogenicity (Geeraedts et al., 2008). This study 
highlighted in particular the importance of TLR7 in driving a particular class of immune 
response – specifically Th1 immunity – reinforcing the notion that PRR triggering controls 
immune response polarization as well as magnitude. In contrast, split virus or subunit 
vaccines, which are less potent but considered safer, showed little TLR7 dependence 
presumably as a result of loss of the packaged viral ssRNA that potently stimulates TLR7 
during production (Geeraedts et al., 2008). Of course these studies into the PRR 
requirements of vaccines have been performed in mouse models and to date the importance 
of PRR signaling for protective immunity in humans has yet to be determined, and may 
show different patterns. 
Evidence for the need for TLR signaling for the activity of inactivated bacterial vaccines 
comes from the whole cell Pertussis vaccine. Although this vaccine contains a wide range of 
bacterial PAMPs, TLR4 and TRIF but not TLR2 knockout mice showed reduced immunity. 
This suggests that LPS is more critical than lipopeptides for induction of adaptive responses 
in this instance (Fransen et al., 2010). 
4.1.4 PRR triggering by subunit vaccines 
At first sight, subunit vaccines should not contain PAMPs because the critical microbial 
‘subunit’ should be an antigen, i.e. target for adaptive – not innate – immune responses. But 
although simpler and purer than whole inactivated vaccines, many current human subunit 
vaccines still contain microbe-derived PAMPs either co-purified with the antigen or in some 
cases the antigenic subunit is itself a PRR agonist. Thus, meningitis vaccines based on 
purified outer membrane vesicle preparations of Neisseria meningitides contain both LPS 
and TLR2-stimulatory lipopeptides, and require TLR4 and TRIF signaling for optimal 
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immune priming (Fransen et al., 2010). As well as PAMPs co-purified with antigenic 
subunits, many non-protein protective antigens such as polysaccharides or lipoproteins can 
directly trigger PRR. For example, the outer-surface lipoprotein (OspA) subunit of Borrelia 
burgdorferi activates TLR2 and has been used as an effective human vaccine against Lyme 
disease. This particular antigenic PAMP not only shows reduced immunogenicity in TLR2 
knockout mice, but human hyporesponsiveness to the vaccine is associated with low TLR1 
expression (Alexopoulou et al., 2002).  
4.1.5 PAMP-free triggering of PRRs by adjuvants 
The sections above have introduced the importance of TLRs in the development of 
immunity following vaccination. It is now becoming apparent that other PRRs, and 
stimulation of alternative proinflammatory pathways, can be important for vaccine 
functionality. There is evidence that some vaccine adjuvants can induce long-lasting and 
protective immune responses independently of TLR-based signalling pathways (Gavin et 
al., 2006; Nemazee et al., 2006). Furthermore, the majority of recently developed human 
adjuvant formulations, such as emulsions (Reed et al., 2009), do not obviously contain 
microbial components and are therefore unlikely to contain PAMPs. The NLRP3 
inflammasome has been shown to be activated by the common adjuvant alum, however it is 
currently debatable as to whether this activation is required for the adjuvant activity of alum 
(De Gregorio et al., 2009; Franchi and Nunez, 2008; Li et al., 2008; McKee et al., 2009). Several 
other PAMP-free adjuvant formulations, including oil emulsions, saponins and 
microparticles made from biodegradeable polymer poly(lactic-co-glycolic acid) also trigger 
NALP3-dependent immune activation (Williams et al., 2010). In addition, the Syk/CARD9 
pathway is activated by the potent adjuvant additive, trehalose 6,6-dibehenate, a synthetic 
mimic of a mycobacterial cell wall component (Werninghaus et al., 2009).  
4.2 Implications of PRR research findings for the development of new vaccines 
There is still a large demand for better vaccines in order to reduce costs, improve potency 
and efficacy, to tackle diseases which currently lack a vaccine (e.g. Human 
Immunodeficiency Virus) and to respond quickly to new challenges from infectious diseases 
(e.g. pandemic influenza). Understanding how PRRs contribute to protective immunity and 
how this can be modulated are key if vaccines are to improve.  
One area of particular importance to vaccine development is the need to rationally design 
new adjuvants with greater potency than current ones such as alum (Mbow et al., 2010; 
Reed et al., 2009; Leroux-Roels, 2010). Selective triggering of different PRRs and DC subsets 
are thought to be major points of control of immune polarization (Iwasaki and Medzhitov, 
2004; Kapsenberg, 2003). It follows therefore that not only are new adjuvants needed, but 
these must be engineered to stimulate the correct PRR on the optimal cell type. The most 
clinically relevant illustration of the benefits of adding PRR agonists to increase adjuvant 
activity is GSK’s adjuvant AS 04, which incorporates the TLR4 agonist monophosphoryl 
lipid A (MPLA) to alum (Didierlaurent et al., 2009). The human papilloma virus virus-like 
particle vaccine Cervarix is formulated with AS 04, which may account for its apparent 
increased potency compared to Gardasil, a similar VLP vaccine that uses alum without 
MPLA (Einstein et al., 2009). Interestingly MPLA appears to preferentially activate TLR4 
signalling through the TRIF:TRAM pathway and not Mal:MYD88 (Mata-Haro et al., 2007). 
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Without doubt the role of synthetic PRR-specific agonists as additives to vaccine adjuvants 
will become a developing and increasingly important field of research. Of course given the 
potent immunostimulatory properties of PRR agonists care will have to be taken to avoid 
potentially damaging, or fatal, systemic effects. 
4.2.1 TLR agonists in adjuvants 
As well as the benefits of adding MPLA to alum, a wide range of TLR agonists have been 
shown to promote immunity when added to antigens. These include TLR2-stimulatory 
lipopeptides such as MALP-2, the TLR5 agonist flagellin, TLR9-stimulatory CpG oligos, 
small molecule TLR7/8 agonists such as imidazoquinolines, the TLR3 agonist polyI:C and 
various modified RNA and DNA oligos that can act on TLR3,7 and/or 9. TLR triggering, 
such as by CpG oligos or imidazoquinolines, frequently promotes Th1 responses (Schnare et 
al., 2001), but there are a number of exceptions, including Th2 induction by lipopeptides and 
flagellin that trigger TLR2 and TLR5 respectively (Didierlaurent et al., 2004; Redecke et al., 
2004). It has become clear that for maximal potency and benefits the TLR agonist requires 
linking in some way with the target antigen. For example, agonists have been covalently 
coupled to proteins; synthesized directly in combination with the TLR agonist; or antigen 
and PRR agonists can be immobilised together on a particulate scaffold. The importance of 
linking PRR agonists with antigen was demonstrated in a recent study where peptides were 
co-encapsulated with a TLR9 agonist using the biodegradeable polymer PLGA; only when 
antigen and CpG oligonucleotides were present in the same PLGA microsphere was an 
effective cytotoxic T cell response achieved (Schlosser et al., 2008). 
4.2.2 Combinatorial PRR triggering 
Just as most microbes contain a number of different PAMPs and trigger several PRR, there is 
a need to combine PRR triggers in adjuvants for synergistic effects, and to closely mimic 
pathogens. The best studied example of synergistic PRR signaling comes from the activation 
of TLR2 combined with signaling through the CLEC dectin-1 (Gantner et al., 2003; 
Underhill, 2007). PRR signaling also synergises with other proinflammatory pathways. 
Major examples include the interplay between T cell feedback signals through CD40 
expressed on PRR-stimulated DC (Schulz et al., 2000), and the requirement of NALP3 for 
maximal response to various PRR including vaccinia (Delaloye et al., 2009). 
5. Conclusions 
Without doubt PRRs have a crucial role to play in the detection of, and response to, 
infectious diseases. The repertoire and versatility of the host in detecting PAMPS and 
associated danger signals is outstanding and continually expanding. In fact this is only 
matched by the steps taken by pathogens to circumvent these defence strategies. As research 
progresses in this field it is becoming increasingly apparent that although the outputs of 
PRR activation are broadly similar – i.e. pro-inflammatory cytokine induction, caspase-1 
processing and IFN induction – the mechanisms by which this takes place are actually 
remarkably subtle. There is significant crosstalk between TLR, NLR, CLR and RLR 
signalling pathways. In addition, there is clear redundancy in function between different 
receptors that helps to ensure appropriate recognition of, and response to, pathogens. The 
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complexity of the signalling crosstalk is only likely to increase as our understanding of these 
systems improves.  
Another key area in which PRR recognition of infectious diseases is becoming increasingly 
important is the development of adaptive immunity. The innate response seems to play a 
vital role in directing the nature of the adaptive response, particularly in relation to driving 
development of particular T-cell subsets. This is a rapidly developing area and the search for 
rational vaccine design makes it critical to infectious disease research. The study of the 
cellular and molecular biology of PRRs has provided a strong theoretical and experimental 
foundation for the rational design of vaccine adjuvants. This new understanding must be 
harnessed to provide a complete toolkit for custom adjuvant design. However, in common 
with other biomedical disciplines, clinical uptake typically lags behind scientific discovery 
and we wait to see how best this knowledge can be transferred to provide clinical benefit.  
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